# TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting

Page: https://stenobird.com/podcast/gynecologic-oncology-update-612940/trop2-and-cdh6-directed-adcs-in-gynecologic-cancers-an-interview-with-dr-ramez-eskander-on-key-presentations-from-the-society-of-gynecologic-oncology-2026-annual-meeting
Text version: https://stenobird.com/podcast/gynecologic-oncology-update-612940/trop2-and-cdh6-directed-adcs-in-gynecologic-cancers-an-interview-with-dr-ramez-eskander-on-key-presentations-from-the-society-of-gynecologic-oncology-2026-annual-meeting.md
Podcast: [Gynecologic Oncology Update](https://stenobird.com/podcast/gynecologic-oncology-update-612940)
Published: 2026-08-01T13:00:00+00:00
Episode link: https://gynecologic-oncology.captivate.fm/episode/5988-sgo26-review-adcsgyn
Audio file: https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/d55eeff4-01ab-41e2-b9a1-5353ebd3dc6d.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/gynecologic-oncology-update-612940/episodes/trop2-and-cdh6-directed-adcs-in-gynecologic-cancers-an-interview-with-dr-ramez-eskander-on-key-presentations-from-the-society-of-gynecologic-oncology-2026-annual-meeting
Duration seconds: 3284

## Resource

Featuring an interview with Dr Ramez Eskander, including the following topics: Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00) Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53) Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58) Current and investigational targets of ADCs in gynecologic cancers (17:14) Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56) Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36) Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34) Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05) Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38) CME information and select publications

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/gynecologic-oncology-update-612940/episodes/trop2-and-cdh6-directed-adcs-in-gynecologic-cancers-an-interview-with-dr-ramez-eskander-on-key-presentations-from-the-society-of-gynecologic-oncology-2026-annual-meeting/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/gynecologic-oncology-update-612940/trop2-and-cdh6-directed-adcs-in-gynecologic-cancers-an-interview-with-dr-ramez-eskander-on-key-presentations-from-the-society-of-gynecologic-oncology-2026-annual-meeting.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.